
LETTERS
TO THE EDITOR

To the 80th Anniversary of B.I. Ionin

Diphenyl[(3,5-di-*tert*-butyl-4-oxo-2,5-cyclohexadienylidene)-methyl]phosphonate in Reactions with *o*-Phenylenediamine

E. M. Gibadullina^a, T. R. Shaekhov^a, A. K. Badrtdinov^b, and A. R. Burilov^a

^a Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center, Russian Academy of Sciences,
ul. Akademika Arbuzova 8, Kazan, Tatarstan, 420088 Russia
e-mail: elmirak@iopc.ru

^b Kazan National Research Technological University, Kazan, Tatarstan, Russia

Received November 13, 2014

Keywords: benzimidazole, cyclization, methylenequinone, *o*-phenylenediamine, hindered phenol

DOI: 10.1134/S1070363215020280

Benzimidazole derivatives containing sterically hindered phenolic moieties exhibit remarkable biological activity [1–3]. Oxidation of 4-(1*H*-benzo[*d*]imidazol-2-yl)-2,6-di-*tert*-butylphenol with lead(IV) oxide yields stable solid phenoxyl radical promising for development of molecular magnetic materials [4]. 4-(1*H*-Benzo[*d*]imidazol-2-yl)-2,6-di-*tert*-butylphenol can be obtained via two classical methods: (a) the Phillips–Ladenburg reaction (interaction of *o*-phenylenediamine with 3,5-di-*tert*-butyl-4-hydroxybenzylcarboxylic acid) [5] and (b) the Weidenhagen reaction (interaction of diaminobenzenes with 3,5-di-*tert*-butyl-4-hydroxybenzylaldehyde) [4, 6]. Benzimidazole derivatives have been prepared via reaction of diaminobenzenes with 3,5-di-*tert*-butyl-4-hydroxybenzyl carboxyimide hydrochloride [7, 8]. An example of *o*-phenylenediamine reaction with *S,S*-ethylenebisthio-2,6-di-*tert*-butyl-4-methylene-2,5-cyclohexadienone affording benzimidazole bearing a hindered phenol moiety has been described [9].

In this report we propose a new method to prepare benzimidazoles containing hindered phenolic moiety based on the reaction of diphenyl[(3,5-di-*tert*-butyl-4-oxo-2,5-cyclohexadienylidene)methyl]phosphonate with *o*-phenylenediamine derivatives (*o*-phenylenediamine, 4-methyl-1,2-diaminobenzene, and 4-nitro-1,2-diaminobenzene).

Interaction of methylenequinones **I** with *o*-phenylenediamine in dioxane upon heating gave a 2 : 1 complex **II** of the benzimidazole derivative with phosphorous acid **II** in high yield. Similarly, the reaction of methylenequinones **I** with 4-methyl-1,2-diaminobenzene and 4-nitro-1,2-diaminobenzene afforded complexes **III** and **IV**, respectively.


The resulting compounds were solids sparingly soluble in organic solvents. Composition and structure of compounds **II–IV** were confirmed by means of elemental analysis, IR, ¹H, ¹³C, and ³¹P NMR spectroscopy.

To conclude, the interaction of diphenyl[(3,5-di-*tert*-butyl-4-oxo-2,5-cyclohexadienylidene)methyl]phosphonate with *o*-phenylenediamine derivatives is a promising way to obtain new benzimidazole derivatives (Scheme 1).

Diphenyl-(3,5-di-*tert*-butyl-4-oxocyclohexa-2,5-dienylidenemethyl)phosphonate **I** was synthesized as described [10].

General preparation procedure. *o*-Phenylenediamine (0.1 mmol) was added to a solution of 0.45 g (0.1 mmol) of methylenequinone **I** in 4 mL of dioxane. The reaction mixture was refluxed during 12 h. The resulting precipitate was filtered off, washed with dioxane, and dried in vacuum (1.5×10^{-2} mmHg) for 1 h at 40°C.

Scheme 1.



4-(1*H*-Benzo[d]imidazol-2-yl)-2,6-di-*tert*-butylphenol (hydrophosphite) (II). Yield 0.27 g (74%), mp >310°C (DMSO). IR spectrum, ν , cm⁻¹: 2961 (CH), 3446 (NH), 3630 (OH). ¹H NMR spectrum, δ , ppm (*J*, Hz): 1.46 s [18H, C(CH₃)₃], 5.94 d (1H, PH, *J*_{PH} 630.0), 7.21 m (2H, H^{6,7}), 7.61 m (2H, H^{5,8}), 7.98 s (2H, H^{3,5}). ¹³C NMR spectrum, δ _C, ppm (*J*, Hz): 29.6 q [C(CH₃)₃], ¹*J*_{CH} 126.0], 35.4 [C(CH₃)₃], 115.0 d (C^{3,5}, ¹*J*_{CH} 163.0), 120.4 (C⁴), 123.1 d (C^{5,8}, ¹*J*_{CH} 160.0), 124.5 d (C^{6,7}, ¹*J*_{CH} 158.0), 138.3 (C^{2,6}), 140.12 (C^{4',9'}), 152.6 (C¹), 157.1 (C²). ³¹P NMR spectrum: δ _P 1.9 ppm (d, *J*_{PH} 630.0 Hz). Mass spectrum (MALDI): *m/z* 322.7399 [*M*]⁺. Found, %: C 69.19; H 7.78; N 7.45; P 4.67. C₄₂H₅₂N₄O₂·H₃PO₃. Calculated, %: C 69.40; H 7.63; N 7.71; P 4.26.

4-(6-Methyl-1*H*-benzo[d]imidazol-2-yl)-2,6-di-*tert*-butylphenol (hydrophosphite) (III). Yield 0.3 g (79%), mp >300°C (DMSO). IR spectrum, ν , cm⁻¹: 2957 (CH), 3443 (NH), 3626 (OH). ¹H NMR spectrum, δ , ppm (*J*, Hz): 1.46 s [18H, C(CH₃)₃], 2.42 s (3H, CH₃), 5.91 d (1H, PH, *J*_{PH} 630.0), 7.00 d (1H, H⁷, ³*J*_{HH} 8.1), 7.35 d (1H, H⁸, ³*J*_{HH} 8.3), 7.45 s (1H, H⁵), 7.93 s (2H, H^{3,5}). ¹³C NMR spectrum, δ _C, ppm (*J*, Hz): 24.6 q (CH₃, ¹*J*_{CH} 125.0), 29.8 [C(CH₃)₃], ¹*J*_{CH} 126.0), 35.8 [C(CH₃)₃], 115.2 d (C^{3,5}, ¹*J*_{CH} 160.0), 120.4 (C⁴), 122.6 d (C^{5,8}, ¹*J*_{CH} 160.0), 125.8 d (C⁷, ¹*J*_{CH} 160.0), 130.8 (C⁶), 138.8 (C^{2,6}), 142.2 (C^{4',9'}), 152.9 (C¹), 158.4 (C²). ³¹P NMR spectrum: δ _P 1.9 ppm (d, *J*_{PH} 630.0 Hz). Mass spectrum (MALDI): *m/z* 336.7262 [*M*]⁺. Found, %: C 68.13; H 7.95; N 7.25; P 4.01. C₄₄H₅₆N₄O₂·H₃PO₃. Calculated, %: C 70.00; H 7.88; N 7.42; P 4.10.

4-(6-Nitro-1*H*-benzo[d]imidazol-2-yl)-2,6-di-*tert*-butylphenol (hydrophosphite) (IV). Yield 0.2 g

(49%), mp >300°C (DMSO). IR spectrum, ν , cm⁻¹: 1538 (NO₂), 2957 (CH), 3470 (NH), 3607 (OH). ¹H NMR spectrum, δ , ppm (*J*, Hz): 1.47 s [18H, C(CH₃)₃], 5.91 d (1H, PH, *J*_{PH} 630.0), 7.71 d (1H, H⁸, ³*J*_{HH} 8.3), 8.01 s (2H, H^{3,5}), 8.08 d (1H, H⁷, ³*J*_{HH} 8.3), 8.42 s (1H, H⁵). ³¹P NMR spectrum: δ _P 1.9 ppm (d, *J*_{PH} 630.0 Hz). Mass spectrum (MALDI): *m/z* 367.9402 [*M*]⁺. Found, %: C 60.32; H 6.74; N 9.85; P 3.54. C₄₂H₅₀N₆O₆·H₃PO₃. Calculated, %: C 61.75; H 6.54; N 10.29; P 3.79.

¹³C NMR spectra were recorded with a Bruker Avance-600 instrument operating at 150 MHz using residual proton signals of the deuterated solvent (DMSO-*d*₆) as reference. ¹H and ³¹P NMR spectra were registered with a Bruker MSL-400 spectrometer operating at 400.13 and 161.94 MHz, respectively. IR spectra were recorded using a Bruker Vector 22 FTIR spectrometer (400–4000 cm⁻¹, mineral oil). Mass spectra (MALDI-TOF) were obtained using an ULTRAFLEX III TOF/TOF Bruker instrument (*p*-nitroaniline as matrix). Elemental analysis was performed using a Carlo-Erba EA 1108 analyzer.

ACKNOWLEDGMENTS

This work was financially supported by Russian Foundation for Basic Research (project 12-03-97041).

REFERENCES

1. Isomura, Y., Ito, N., Homma, H., Abe, T., and Kubo, K., *Chem. Pharm. Bull.*, 1983, vol. 31, no. 9, p. 3168. DOI: 10.1248/cpb.31.3179.
2. Ohemeng, K.A. and Nguyen, V.N., WO Patent 9911627, 1999.
3. Sokolova, N.Yu., Kuznetsov, V.A., Garabadzhiu, A.V.,

- Ginzburg, L.F., Dobrynin, Ya.V., Nikolaeva, T.G., Fin'ko, V.E., and Ivanova, T.P., *Pharm. Chem. J.*, 1990, vol. 24, no. 1, p. 40. DOI: 10.1007/BF00769384.
4. Xie, Ch. and Lahti, P.M., *Tetrahedron Lett.*, 1999, vol. 40, p. 4305. DOI: 10.1016/S0040-4039(99)00784-4.
 5. GB Patent 1260793, 1972.
 6. Sando, S., Narita, A., and Aoyama, Y., *ChemBioChem*, 2007, vol. 8, p. 1795. DOI: 10.1002/cbic.200700325.
 7. Sokolova, N.Yu., Kuznetsov, V.A., Garabadzhiu, A.V., Sokolov, V.V., and Ginak, A.I., *Zh. Org. Khim.*, 1991, vol. 27, p. 631.
 8. Kelarev, V.I., Shvekhgeimer, S.G., Koshelev, V.N., Shvekhgeimer, G.A., and Lunin, A.F., *Chem. Heterocycl. Compd.*, 1984, vol. 20, no. 7, p. 721. DOI: 10.1007/BF00506956.
 9. Gompper, R., Kutter, E., and Schmidt, R.R., *Chem. Ber.*, 1965, vol. 98, p. 1374. DOI: 10.1002/cber.19650980504.
 10. Shaekhov, T.R., Gibadullina, E.M., Voronina, Yu.K., Syakaev, V.V., Sharafutdinova, D.R., Burilov, A.R., and Pudovik, M.A., *Russ. Chem. Bull. Int. Ed.*, vol. 60, no. 10, p. 1999. DOI: 10.1007/s11172-011-0303-8.